Results 111 to 120 of about 22,494 (197)

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response. [PDF]

open access: yesAnn Hematol, 2023
Ferreira APS   +11 more
europepmc   +1 more source

The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. [PDF]

open access: yesPLoS Pathog, 2023
Cleverley TL   +7 more
europepmc   +1 more source

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. [PDF]

open access: yesAnn Hematol, 2023
Ferreira APS   +11 more
europepmc   +1 more source

Use of Imatinib in the Prevention of Heterotopic Ossification [PDF]

open access: yes, 2018
Background: Heterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification.
Lane, Joseph   +5 more
core  

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

open access: yesТерапевтический архив, 2010
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease.
Ol'ga Veniaminovna Stakhina   +7 more
doaj  

Home - About - Disclaimer - Privacy